SK16682001A3 - Liečivo na liečenie angiogenézy - Google Patents

Liečivo na liečenie angiogenézy Download PDF

Info

Publication number
SK16682001A3
SK16682001A3 SK1668-2001A SK16682001A SK16682001A3 SK 16682001 A3 SK16682001 A3 SK 16682001A3 SK 16682001 A SK16682001 A SK 16682001A SK 16682001 A3 SK16682001 A3 SK 16682001A3
Authority
SK
Slovakia
Prior art keywords
acid
diphosphonic acid
bisphosphonate
angiogenesis
treatment
Prior art date
Application number
SK1668-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Tetsuji Okuno
Jonathan Green
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK16682001(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9911926.5A external-priority patent/GB9911926D0/en
Priority claimed from GBGB9925131.6A external-priority patent/GB9925131D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK16682001A3 publication Critical patent/SK16682001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK1668-2001A 1999-05-21 2000-05-19 Liečivo na liečenie angiogenézy SK16682001A3 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9911926.5A GB9911926D0 (en) 1999-05-21 1999-05-21 Organic compounds
GBGB9925131.6A GB9925131D0 (en) 1999-10-22 1999-10-22 Organic compounds
PCT/EP2000/004562 WO2000071104A2 (en) 1999-05-21 2000-05-19 Use of bisphosphonic acids for treating angiogenesis

Publications (1)

Publication Number Publication Date
SK16682001A3 true SK16682001A3 (sk) 2002-04-04

Family

ID=26315578

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1668-2001A SK16682001A3 (sk) 1999-05-21 2000-05-19 Liečivo na liečenie angiogenézy

Country Status (21)

Country Link
US (2) US20020142996A1 (cg-RX-API-DMAC7.html)
EP (1) EP1178810B8 (cg-RX-API-DMAC7.html)
JP (1) JP2003500352A (cg-RX-API-DMAC7.html)
KR (1) KR100763064B1 (cg-RX-API-DMAC7.html)
CN (1) CN1202828C (cg-RX-API-DMAC7.html)
AT (1) ATE293450T1 (cg-RX-API-DMAC7.html)
AU (1) AU775079B2 (cg-RX-API-DMAC7.html)
BR (1) BR0010808A (cg-RX-API-DMAC7.html)
CA (1) CA2374049A1 (cg-RX-API-DMAC7.html)
DE (1) DE60019580T2 (cg-RX-API-DMAC7.html)
DK (1) DK1178810T3 (cg-RX-API-DMAC7.html)
ES (1) ES2240106T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0201329A3 (cg-RX-API-DMAC7.html)
IL (2) IL146520A0 (cg-RX-API-DMAC7.html)
NO (1) NO322212B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ515541A (cg-RX-API-DMAC7.html)
PL (1) PL351674A1 (cg-RX-API-DMAC7.html)
PT (1) PT1178810E (cg-RX-API-DMAC7.html)
SK (1) SK16682001A3 (cg-RX-API-DMAC7.html)
TW (1) TWI224504B (cg-RX-API-DMAC7.html)
WO (1) WO2000071104A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1296689T3 (da) * 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
EP1591122B1 (en) * 2000-06-20 2012-09-26 Novartis AG Method of administering bisphosphonates
DE60143964D1 (de) * 2001-02-06 2011-03-10 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
BR0209365A (pt) * 2001-05-02 2004-06-08 Novartis Ag Usos farmacêuticos de bisfosfonatos
ES2336312T3 (es) * 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
BR0308901A (pt) 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
ATE441420T1 (de) * 2002-12-02 2009-09-15 Innate Pharma Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
US20060281714A1 (en) * 2003-07-21 2006-12-14 Johann Zimmermann Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
US7618953B2 (en) † 2004-02-26 2009-11-17 Zentiva, A.S. Amorphous forms of risedronate monosodium
ES2358269T3 (es) * 2004-08-23 2011-05-09 Teva Pharmaceutical Industries Ltd Forma cristalina del ibandronato sódico y procedimientos para su preparación.
US7914810B2 (en) 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
KR101813728B1 (ko) * 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2015018659A1 (en) * 2013-08-05 2015-02-12 Vib Vzw Glutamine synthetase inhibitors for inhibition of pathological angiogenesis
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
DE3425812A1 (de) * 1984-07-13 1986-01-16 Deutsches Krebsforschungszentrum, 6900 Heidelberg Neue 1-hydroxy-1,1-diphosphonsaeureverbindungen, verfahren zu ihrer herstellung und pharmakologische zubereitungen, insbesondere zur behandlung von knochentumoren
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
SE9402001D0 (sv) * 1994-06-09 1994-06-09 Leiras Oy Pyridylbisphosphonates for use as a therapeutical agent
IT1290444B1 (it) * 1997-03-27 1998-12-03 Boehringer Mannheim Italia Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale
DE69803291T2 (de) * 1997-07-22 2002-08-08 Merck & Co Inc Methoden zur verhinderung von knochenresorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EP0998934A4 (en) * 1997-12-25 2005-09-14 Toray Industries REMEDIES AGAINST INTRAMEDULLARY DISEASES
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
WO1999038998A1 (en) * 1998-01-29 1999-08-05 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance

Also Published As

Publication number Publication date
PL351674A1 (en) 2003-05-19
IL146520A0 (en) 2002-07-25
WO2000071104A3 (en) 2001-07-19
NO322212B1 (no) 2006-08-28
DK1178810T3 (da) 2005-07-11
CA2374049A1 (en) 2000-11-30
DE60019580D1 (de) 2005-05-25
CN1202828C (zh) 2005-05-25
JP2003500352A (ja) 2003-01-07
BR0010808A (pt) 2002-08-27
HUP0201329A2 (en) 2002-08-28
NO20015638D0 (no) 2001-11-19
EP1178810A2 (en) 2002-02-13
IL146520A (en) 2006-09-05
NO20015638L (no) 2002-01-15
EP1178810B1 (en) 2005-04-20
NZ515541A (en) 2003-03-28
CN1384749A (zh) 2002-12-11
US20040176327A1 (en) 2004-09-09
KR100763064B1 (ko) 2007-10-04
TWI224504B (en) 2004-12-01
WO2000071104A2 (en) 2000-11-30
HUP0201329A3 (en) 2005-02-28
ATE293450T1 (de) 2005-05-15
AU5214100A (en) 2000-12-12
ES2240106T3 (es) 2005-10-16
PT1178810E (pt) 2005-08-31
AU775079B2 (en) 2004-07-15
KR20010113830A (ko) 2001-12-28
US20020142996A1 (en) 2002-10-03
EP1178810B8 (en) 2005-07-27
DE60019580T2 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
KR100763064B1 (ko) 제약 조성물 및 용도
JP4722375B2 (ja) ビホスホネートの投与法
RU2325913C2 (ru) Применение золедроновой кислоты, ее солей, гидратов и способ антиноцицептивного или антиаллодинического лечения боли, способ лечения невропатической боли
US5965547A (en) Use of certain methanebishosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
SK13512003A3 (sk) Použitie N-bisfosfonátu na prípravu liečiva na liečenie kostných metastáz spojených s karcinómom prostaty
JP2006506365A (ja) ビスホスホネートの投与方法
JP6261512B2 (ja) 心機能障害を治療及び/又は低減するためのビスホスホネート組成物並びに方法
US20030212048A1 (en) Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
RU2261100C2 (ru) Применение бисфосфоновых кислот для лечения ангиогенеза
CA2183764C (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration